|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preferentially expressed antigen in melanoma (PRAME) has been studied as a tool for prognostication of uveal melanomas, and immunotherapy against PRAME-expressing tumor cells has already shown promise.
|
31375769 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The likelihood of positive histopathologic diagnosis of melanoma is higher in PLA results that are positive for both LINC00518 and PRAME.
|
30004988 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diffuse nuclear immunoreactivity for PRAME was found in 87% of metastatic and 83.2% of primary melanomas.
|
30045064 |
2018 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PRAME levels were significantly (P less than 0.001) increased based on normalized Ct cycle counts (lower cycle counts indicate higher expression levels) in melanomas (mean Ct 33.83 + 0.54, 95% CI 32.85-34.80) when compared to Spitz nevi (mean Ct 37.21 + 0.98, 95% CI 35.41-39.01) or common nevi (mean Ct 36.94 + 0.80, 95% CI 35.47-38.40), respectively.
|
29742191 |
2018 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, our findings suggest that MZF1, via stimulation of PRAME expression, may be a potential prognostic and therapeutic target in melanoma.
|
28634046 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of long intergenic non-protein coding RNA 518 (LINC00518) and preferentially expressed antigen in melanoma (PRAME) genes, obtained via noninvasive adhesive patch biopsy, is a sensitive and specific method for detection of cutaneous melanoma.
|
28445578 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We established LINC00518 and PRAME in both adhesive patch melanoma samples and underlying formalin fixed paraffin embedded (FFPE) samples of surgically excised primary melanomas and in melanoma lymph node metastases.
|
27707590 |
2017 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All target qPCRs demonstrated a good specificity (100%) and sensitivity (with a limit of detection of 1-2 copies), which allows reliable detection of gene expression changes of LINC and PRAME between melanomas and nonmelanomas.
|
27505074 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report that the protein PRAME, a tumor-associated antigen isolated from a melanoma, plays a role in preventing the proliferation and metastasis of breast cancer cells.
|
27632898 |
2016 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, we sought to define a threshold value for positive PRAME expression (PRAME+) in a large dataset, identify factors associated with PRAME expression, evaluate the prognostic value of PRAME in Class 2 uveal melanomas, and determine whether PRAME expression is associated with aberrant hypomethylation of the PRAME promoter.
|
27486988 |
2016 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of SOX9 in both human and mouse melanoma cell lines induced cell cycle arrest by increasing p21 transcription and restored sensitivity to RA by downregulating expression of PRAME, a melanoma antigen.
|
19273910 |
2009 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Conversely, knockdown of PRAME expression by RNA interference in RA-resistant human melanoma restores RAR signaling and reinstates sensitivity to the antiproliferative effects of RA in vitro and in vivo.
|
16179254 |
2005 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Conversely, knockdown of PRAME expression by RNA interference in RA-resistant human melanoma restores RAR signaling and reinstates sensitivity to the antiproliferative effects of RA in vitro and in vivo.
|
16179254 |
2005 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reverse transcription-PCR revealed a highly heterogeneous expression of MAGE-A1, -A2, -A3, -A4, -A6, GAGE 1-6, SSX 1-5, and PRAME among melanoma clones.
|
15604288 |
2004 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of the PRAME gene (preferentially expressed antigen of melanoma) was measured by quantitative reverse transcriptase polymerase chain reaction in 50 children with newly diagnosed acute myeloid leukemia (AML), three samples of CD34(+) stem cells, six bone marrow samples, and 10 peripheral blood samples of healthy donors, as well as three AML cell-lines (KG-1, U937, and HL-60).
|
11943337 |
2002 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, a PRAME-positive leukaemia cell line and fresh leukaemic cells were found to be susceptible to lysis by PRAME-specific CTLs established from a patient with melanoma, suggesting that the PRAME peptide can also be a target leukaemia antigen for T cells.
|
11298586 |
2001 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.
|
9753074 |
1998 |